| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.064 | 0.05 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.05 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |